Metagenomi (MGX) Stock Forecast & Price Target

$2.72

-0.18 (-6.21%)

(As of 09/6/2024 ET)

Metagenomi - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Metagenomi in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for MGX.

Consensus Price Target

$15.50
469.85% Upside

High Forecast	$25.00
Average Forecast	$15.50
Low Forecast	$6.00

According to the 7 analysts' twelve-month price targets for Metagenomi, the average price target is $15.50. The highest price target for MGX is $25.00, while the lowest price target for MGX is $6.00. The average price target represents a forecasted upside of 469.85% from the current price of $2.72.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$15.50	$17.83	$17.83	N/A
Forecasted Upside	469.85% Upside	80.17% Upside	75.67% Upside	N/A

Get Metagenomi Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.

Ad Golden Crest

Biden's Successor: The Radical Threat to YOUR Savings!

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

MGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Metagenomi Stock vs. The Competition

Type	Metagenomi	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	469.85% Upside	1,206.56% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/6/2024	HC Wainwright 2 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00	+141.38%
9/5/2024	Chardan Capital 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00	+419.03%
8/15/2024	BMO Capital Markets 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$22.00 ➝ $17.00	+451.95%
5/2/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$16.00 ➝ $6.00	-14.77%
3/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
3/5/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$23.00	+91.03%
3/5/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$25.00	+107.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:28 PM ET.

MGX Forecast - Frequently Asked Questions

What is Metagenomi's forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Metagenomi is $15.50, with a high forecast of $25.00 and a low forecast of $6.00.
Should I buy or sell Metagenomi stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Metagenomi in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MGX shares.
Does Metagenomi's stock price have much upside?: According to analysts, Metagenomi's stock has a predicted upside of 132.56% based on their 12-month stock forecasts.
What analysts cover Metagenomi?: Metagenomi has been rated by research analysts at BMO Capital Markets, Chardan Capital, and HC Wainwright in the past 90 days.
Do Wall Street analysts like Metagenomi more than its competitors?: Analysts like Metagenomi more than other "medical" companies. The consensus rating score for Metagenomi is 2.86 while the average consensus rating score for "medical" companies is 2.77. Learn more on how MGX compares to other companies.